Dena Leeman

Dena Leeman is a Senior Scientist II & Program Team Lead at Scribe Therapeutics, focusing on building the next-generation of in vivo CRISPR-based genetic medicines. Prior to this role, Dena held positions at Genentech and Stanford University School of Medicine, where Dena conducted research in regenerative medicine and neural stem cell function and aging. Dena holds a Ph.D. in Stem Cell Biology, Aging, and Cancer from Stanford University School of Medicine and a Bachelor's Degree in Biology from Brandeis University.